Skip to content
Baltimore News Journal – Lifestyle
Author:
Raziel Therapeutics; Fosun Pharma
Raziel Therapeutics and Fosun Pharma Announce Positive Phase 3 Results for RZL-012 in Submental Fat Reduction, Clearing the Path to a China NDA Filing
September 2, 2026